JP2007532486A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532486A5
JP2007532486A5 JP2007504145A JP2007504145A JP2007532486A5 JP 2007532486 A5 JP2007532486 A5 JP 2007532486A5 JP 2007504145 A JP2007504145 A JP 2007504145A JP 2007504145 A JP2007504145 A JP 2007504145A JP 2007532486 A5 JP2007532486 A5 JP 2007532486A5
Authority
JP
Japan
Prior art keywords
tfpi
composition
analog
administration
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007504145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009097 external-priority patent/WO2005110059A2/en
Publication of JP2007532486A publication Critical patent/JP2007532486A/ja
Publication of JP2007532486A5 publication Critical patent/JP2007532486A5/ja
Pending legal-status Critical Current

Links

JP2007504145A 2004-03-17 2005-03-17 組織因子経路インヒビターの投与による重度の市中肺炎の処置 Pending JP2007532486A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468104P 2004-03-17 2004-03-17
PCT/US2005/009097 WO2005110059A2 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number Publication Date
JP2007532486A JP2007532486A (ja) 2007-11-15
JP2007532486A5 true JP2007532486A5 (enExample) 2008-05-29

Family

ID=35394617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504145A Pending JP2007532486A (ja) 2004-03-17 2005-03-17 組織因子経路インヒビターの投与による重度の市中肺炎の処置

Country Status (16)

Country Link
US (1) US20080286279A1 (enExample)
EP (1) EP1729791A2 (enExample)
JP (1) JP2007532486A (enExample)
KR (1) KR20070007336A (enExample)
CN (1) CN101426520A (enExample)
AU (1) AU2005244249A1 (enExample)
BR (1) BRPI0508992A (enExample)
CA (1) CA2560103A1 (enExample)
IL (1) IL178115A0 (enExample)
MX (1) MXPA06010587A (enExample)
NO (1) NO20064674L (enExample)
RU (1) RU2006136267A (enExample)
SG (1) SG150552A1 (enExample)
TN (1) TNSN06295A1 (enExample)
WO (1) WO2005110059A2 (enExample)
ZA (1) ZA200608413B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN112587522B (zh) * 2020-12-03 2022-11-25 中国海洋大学 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) * 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6345230A (ja) * 1986-04-01 1988-02-26 Central Glass Co Ltd ブロモベンゾトリフルオリドの製造方法
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) * 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5569644A (en) * 1995-05-18 1996-10-29 The Lubrizol Corporation Additive combinations for lubricants and functional fluids
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
DK1602667T3 (da) * 1995-06-07 2007-07-23 Novartis Vaccines & Diagnostic Vandig formulering omfattende TFPI og solubiliseringsmidler
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6011136A (en) * 1995-11-21 2000-01-04 Novartis Ag Cyclopeptolides
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
KR100442758B1 (ko) * 1996-03-25 2004-10-06 사이단호진 가가쿠오요비겟세이료호겐쿠쇼 조직인자응고계억제제함유혈관신생저해제
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
AR015598A1 (es) * 1997-04-28 2001-05-16 Lilly Co Eli FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
BR9914735A (pt) * 1998-10-22 2001-07-03 Lilly Co Eli Processo para tratamento de sépsia
DE69906568T2 (de) * 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
WO2000077246A2 (en) * 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
JP2003521938A (ja) * 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインc誘導体
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DE60217835D1 (en) * 2001-02-28 2007-03-15 John H Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
EP1383885A4 (en) * 2001-04-04 2005-11-30 American Diagnostica Inc METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EA200400548A1 (ru) * 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
US20020198138A1 (en) * 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Similar Documents

Publication Publication Date Title
JP2005506345A5 (enExample)
Van Miert Pro‐inflammatory cytokines in a ruminant model: Pathophysiological, pharmacological, and therapeutic aspects
Waage et al. Current understanding of the pathogenesis of gram-negative shock
JP2007515469A5 (enExample)
O'Brien et al. Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products
US20110165121A1 (en) Use of pegylated type iii interferons for the treatment of hepatitis c
US20220363750A1 (en) Arthritis treatment
JP2002544174A5 (enExample)
JP2005515214A5 (enExample)
RU2010142309A (ru) Способы лечения псориаза
FI4267105T3 (fi) Vasta-ainekoostumuksia ja niiden käyttömenetelmiä
RU2577299C2 (ru) Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
JP6485970B2 (ja) 自己免疫疾患の治療のための併用療法
US20230212278A1 (en) Pharmaceutical composition of anti-il-17a antibodies and use thereof
US5660826A (en) Therapeutic sepsis treatment using antagonists to PTHrP
US5730976A (en) Method for treating macrophage pathogen infections by TGF-B antagonists
Mittelman et al. A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion
JP2023522196A (ja) 化膿性汗腺炎の治療
JP2020531523A5 (enExample)
JP2007532486A5 (enExample)
JPWO2021123902A5 (enExample)
JP2004538275A5 (enExample)
JP2013542206A (ja) C型肝炎ウイルス感染症の新規治療
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗IL-α抗体
DK2694090T3 (en) PHARMACEUTICALS CONTAINING RECOMBINANT MISTELTE LECTINES FOR TREATMENT OF THE ORAL MELANOME